NeOnc Technologies(NTHI)

Focus: NeOnc Technologies is a public biotech company focused on non-invasive cancer therapies, specifically targeting CNS tumors and glioblastomas with a pipeline of early-stage programs.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Total Funding

$10M

Open Jobs

About NeOnc Technologies

AI assessmentNot Hiring

No open roles listed right now. Follow NeOnc Technologies to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$83K

FY2025

Pipeline & Clinical Trials

NEO100

Pediatric Tumor of CNS

Phase 1

Clinical Trials (1)

NCT06357377A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors

Phase 1

Help build intelligence for NeOnc Technologies

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to work on unmet needs in pediatric and adult CNS cancers with innovative non-invasive approaches
Early-stage biotech offers hands-on impact and potential equity upside in a publicly-traded company
Focused pipeline in high-value oncology market with multiple Phase 1/2 programs advancing

Watch Out For

Severe financial distress: $11.9M net loss in FY 2025 with only $65K cash on hand and $83K revenue
No active hiring (0 open positions) and extreme R&D intensity (3669%) signals resource constraints and potential runway risk
No marketed products, no Phase 3 programs, and no publications suggest limited clinical validation or scientific visibility

Generated by Claude from NeOnc Technologies's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Perillyl alcohol

Glioblastoma Multiforme

Phase 1/2

Clinical Trials (1)

NCT02704858Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma

Phase 1/2

NEO212 Oral Capsule

Diffuse Astrocytoma, IDH-Mutant

Phase 1/2

Clinical Trials (1)

NCT06047379Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Phase 1/2

NEO100

Residual, Progressive or Recurrent Grade II or III Meningioma

Phase 2

Clinical Trials (1)

NCT05023018NEO100 and High-Grade Meningioma

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2008

Portfolio: 4 clinical trials

Top TAs: Oncology

SEC Filings: 1 available

Therapeutic Area Focus

Oncology

3 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$83K

R&D Spend

$3M(3669%)

Net Income

-$12M

Cash

$65K

Source: SEC 10-K Filing

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo